Phathom says VOQUEZNA cost-effectiveness model shows drug cost-effective vs PPIs in erosive GERD
PHAT•PHAT•PHAT•PHAT•Phathom Pharmaceuticals said a lifetime economic model indicated VOQUEZNA could be cost-effective versus PPIs for erosive GERD, with potential net-price savings and fewer long-term complications. Other conference data showed consistent benefits across BMI groups in non-erosive GERD and more severe baseline disease among VOQUEZNA starters than prescription PPI starters.
Phathom Pharmaceuticals flagged cost-effectiveness results for VOQUEZNA that had been presented at ACG 2026 in Nashville on October 9-14. A lifetime economic model indicated the drug could be cost-effective versus PPIs for erosive GERD, with potential net-price savings and fewer long-term GERD complications.
Other ACG 2026 presentations reported consistent VOQUEZNA benefits across BMI subgroups in non-erosive GERD. Real-world data showed VOQUEZNA starters had more severe baseline disease than prescription PPI starters.
